Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP2: Duration of IV Antibiotics for CF Exacerbations
NCT02781610Phase 4Completed
- Start
- Jun 2016
- Primary completion
- Mar 2020
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in cystic fibrosis (CF) (4 arms). Primary endpoint: Absolute Change in FEV1 % Predicted. Started Jun 2016; status: completed.
02
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02781610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02781610.